摘要
目的分析丹红注射液在老年缺血性心脑血管疾病治疗中的临床使用价值。方法选择2019年12月至2020年9月期间收治入院的80例老年缺血性心脑血管疾病患者,以奇偶数方式分组,对照组采用常规治疗,观察组联合采用丹红注射液治疗,比较两组的治疗效果、临床疗效和复发率、神经功能、活动能力等。结果观察组患者的治疗总有效率比对照组高,差异有统计学意义(χ^(2)=5.1647,P<0.05);观察组治疗后hs-CRP为(3.45±1.32)mg/L,Hcy为(13.54±2.17)μmol/L,CEC为(6.61±1.08)cells/μL,均低于对照组,差异有统计学意义(P<0.05);观察组复发率比对照组低,差异有统计学意义(χ^(2)=5.0000,P<0.05);观察组治疗后NIHSS评分降低,BI指数及ADL评分升高,分别是(5.64±1.43)分、(74.29±3.76)分、(74.12±3.09)分,差异有统计学意义(P<0.05)。结论丹红注射液用于老年缺血性心脑血管疾病的治疗效果较好,可以减轻患者炎性反应,降低血栓形成风险,提升斑块稳定性,减轻神经功能损伤,提升患者的活动能力,控制复发率,值得临床推广。
Objective To analyze the clinical value of Danhong injection in the treatment of senile ischemic cardio-cerebrovascular diseases. Methods Eighty elderly patients with ischemic cardio-cerebrovascular diseases who were admitted to hospital from December 2019 to September 2020 were divided into 2 groups according to the odd-even method. The control group was treated with conventional treatment, and the observation group was treated with Danhong injection. The therapeutic effects, clinical efficacy, recurrence rates, neurological function and mobility of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P <0.05, χ^(2)=5.1647). After treatment, in the observation group, the hsCRP was(3.45±1.32) mg/L, and the Hcy was(13.54±2.17) μmol/L,and the CEC was(6.61±1.08) cells/μL, which were lower than those in the control group, and the differences were statistically significant(P<0.05). The recurrence rate of the observation group was lower than that of the control group, and the difference was statistically significant(χ^(2)=5.0000, P <0.05). In the observation group, the NIHSS score was lower, while the BI in dex and ADL score were higher, and they were(5.64 ±1.43) points,(74.29 ±3.76) points and(74.12 ±3.09) points, respectively, with statistically significant differences(P<0.05). Conclusion Salvia miltiorrhiza injection has good therapeutic effect on senile ischemic cardio-cerebrovascular diseases, which can reduce patients’ inflammatory response, reduce the risk of thrombosis, improve plaque stability, reduce neurological damage, improve patients’ activity ability, and control the recurrence rate,which is worthy of clinical promotion.
作者
胡倩
HU Qian(Department of Senile Diseases,Central Hospital of Zaozhuang Mining Group,Zaozhuang277000,China)
出处
《中国现代医生》
2021年第35期102-104,108,共4页
China Modern Doctor
关键词
丹红注射液
老年缺血性心脑血管疾病
临床疗效
血栓
复发率
Danhong injection
Senile ischemic cardio-cerebrovascular diseases
Clinical efficacy
Thrombus
Recurrence rate
